Short Interest in Beyond Air, Inc. (NASDAQ:XAIR) Declines By 24.4%

Beyond Air, Inc. (NASDAQ:XAIR) was the recipient of a significant drop in short interest in the month of December. As of December 15th, there was short interest totalling 1,180,000 shares, a drop of 24.4% from the November 30th total of 1,560,000 shares. Based on an average daily trading volume, of 751,200 shares, the short-interest ratio is currently 1.6 days.

Hedge Funds Weigh In On Beyond Air

A hedge fund recently bought a new stake in Beyond Air stock. Soros Fund Management LLC bought a new position in shares of Beyond Air, Inc. (NASDAQ:XAIR) during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 1,476,626 shares of the company’s stock, valued at approximately $573,000. Soros Fund Management LLC owned approximately 3.13% of Beyond Air at the end of the most recent reporting period. 31.50% of the stock is owned by hedge funds and other institutional investors.

Beyond Air Stock Performance

XAIR stock opened at $0.44 on Friday. Beyond Air has a 1 year low of $0.30 and a 1 year high of $2.20. The stock has a market capitalization of $31.76 million, a price-to-earnings ratio of -0.31 and a beta of -0.23. The company has a debt-to-equity ratio of 0.37, a quick ratio of 5.38 and a current ratio of 5.76. The stock’s fifty day moving average is $0.48 and its two-hundred day moving average is $0.53.

Beyond Air (NASDAQ:XAIR) last issued its quarterly earnings data on Monday, November 11th. The company reported ($0.28) earnings per share for the quarter, beating the consensus estimate of ($0.30) by $0.02. Beyond Air had a negative net margin of 2,369.17% and a negative return on equity of 227.29%. The firm had revenue of $0.80 million for the quarter, compared to the consensus estimate of $1.19 million. During the same period last year, the firm posted ($0.51) EPS. On average, research analysts predict that Beyond Air will post -0.78 EPS for the current year.

Beyond Air Company Profile

Beyond Air, Inc operates as a commercial-stage medical device and biopharmaceutical company in the United States. The company engages in the development of LungFit platform, a nitric oxide generator and delivery system. It offers LungFit PH for the treatment of persistent pulmonary hypertension of the newborn.